Beactica receives CIR (French Research Tax Credit) accreditation
Uppsala, Sweden, 11 November 2014
Beactica today announced that it has received CIR accreditation from the French Ministry of Higher Education and Research.
The French R&D tax credit initiative ('Crédit d'Impôt Recherche', CIR) gives eligible research-based companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to Beactica.
"We are delighted to receive this accreditation as it allows Beactica's current and future customers in France to benefit from a tax relief of up to 30% of their R&D expenditure with us”, said Beactica COO, Dr Malin Elinder.
For further information concerning the Crédit d'Impôt sur la Recherche, please refer to the website of the French Ministère de l'Enseignement Supérieur et de la Recherche: http://www.enseignementsup-recherche.gouv.fr.
For additional information please contact Dr Malin Elinder, Beactica COO, +46 18 560880.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in oncology and CNS, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as the leader in fragment-based drug discovery using SPR biosensor technology.